Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds

Patent 5026687 Issued on June 25, 1991. Estimated Expiration Date:

January 3, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

3817982

Immortalized T-lymphocyte cell line for testing HTLV-III inactivation
Patent #: 4704357
Issued on: 11/03/1987
Inventor: Mitsuya , et al.

Antiviral compositions and methods Patent #: 4861759
Issued on: 08/29/1989
Inventor: Mitsuya , et al.

Inventors

Assignee

The United States of America as represented by the Administrator of the

Application

No. 460490 filed on 01/03/1990

US Classes:

514/45, Purines (including hydrogenated) (e.g., adenine, guanine, etc.)514/43, Nitrogen containing hetero ring514/50, 2,4-diketone pyrimidine or derivative (e.g., uracil, etc.)514/81, Nonshared hetero atoms in at least two rings of the polycyclo ring system514/637, Benzene ring containing536/27.14, Multideoxy or didehydro536/27.8, Chalcogen bonded directly to the 6- or 2-position of a purine ring system (e.g., inosine, etc.)536/28.54Alkyl, or substituted alkyl, bonded directly to the 5-position of the diazine ring (e.g., thymidine, 5-methyl uridine, etc.)

Examiners

Primary: Brown, Johnnie R.
Assistant: Crane, L. Eric

Attorney, Agent or Firm

Birch, Stewart, Kolasch & Birch

Foreign Patent References

0206497 EP. 12/13/1986
0302760 EP. 02/13/1989
62-01284 JP. 03/13/1987

International Class

A61K 031/70

Abstract

A preferred method and dosages for the short and long-term treatment of human retroviral infections, or retroviral-like infections, including acquired immunodeficiency syndrome (AIDS) and other manifestations of human immunodeficiency virus (HIV) infection, with 2',3'-dideoxyinosine (ddl) are disclosed, along with a protocol for halting and restarting 2',3'-dideoxyinosine to minimize certain side effects.